{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:01:22Z","timestamp":1788804082814,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Understanding the changes in drug disposition of intravenous anesthetics in patients with obesity and administering appropriate doses are critical to avoid intraoperative awareness with recall because of underdosing and over-sedation and delayed emergence due to overdosing. Pharmacokinetic simulation or target-controlled infusion (TCI) using models that have been adapted to patients with obesity are necessary to select appropriate dosing regimens. This review aimed to describe the pharmacokinetic concepts underpinning the use of intravenous anesthetics, including propofol, remifentanil, and remimazolam, in patients with obesity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In the last 5\u200ayears, a series of pharmacokinetic models for propofol, remifentanil, and remimazolam that were estimated from populations that included obese patients have been published. These new pharmacokinetic models can be considered \u2018second generation\u2019 compared with earlier models in that they expand the range of covariate effects (e.g. the extremes of body weight and age) accounted for by the models. The predictive performances of each pharmacokinetic model have been shown in the literature to be within clinically acceptable limits. Among them, the propofol model by Eleveld <jats:italic toggle=\"yes\">et al.<\/jats:italic> has been externally validated and has shown reasonable predictive accuracy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Pharmacokinetic simulations or TCI using pharmacokinetic models that account for the influence of obesity on a drug's disposition are essential to predict plasma\/effect-site concentrations of intravenous anesthetics and understand the temporal profile of drug concentrations and effect in patients with obesity, particularly severe obesity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aco.0000000000001280","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T13:07:13Z","timestamp":1686748033000},"page":"414-421","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["How obesity affects the disposition of intravenous anesthetics"],"prefix":"10.1097","volume":"36","author":[{"given":"Shinju","family":"Obara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"R1-20250601","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R2-20250601","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/ALN.0000000000001635","article-title":"Disposition of remifentanil in obesity: a new pharmacokinetic model incorporating the influence of body mass","volume":"126","author":"Kim","year":"2017","journal-title":"Anesthesiology"},{"key":"R3-20250601","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40262-015-0277-z","article-title":"Prediction of fat-free mass in children","volume":"54","author":"Al-Sallami","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"R4-20250601","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1345\/aph.19381","article-title":"The origin of the \u201cideal\u201d body weight equations","volume":"34","author":"Pai","year":"2000","journal-title":"Ann Pharmacother"},{"key":"R5-20250601","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00000542-199304000-00008","article-title":"Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study","volume":"78","author":"Servin","year":"1993","journal-title":"Anesthesiology"},{"key":"R6-20250601","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/bja\/aei195","article-title":"Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients","volume":"95","author":"Shibutani","year":"2005","journal-title":"Br J Anaesth"},{"key":"R7-20250601","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/bja\/ael321","article-title":"Predictive performance of 'Servin's formula\u2019 during BIS-guided propofol-remifentanil target-controlled infusion in morbidly obese patients","volume":"98","author":"Albertin","year":"2007","journal-title":"Br J Anaesth"},{"key":"R8-20250601","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/EJA.0b013e328329c6e2","article-title":"Total intravenous anaesthesia to obese patients: largely guesswork?","volume":"26","author":"Coetzee","year":"2009","journal-title":"Eur J Anaesthesiol"},{"key":"R9-20250601","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/bja\/aeq195","article-title":"Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model","volume":"105","author":"Cortinez","year":"2010","journal-title":"Br J Anaesth"},{"key":"R10-20250601","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1152\/jappl.1967.23.5.621","article-title":"Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr","volume":"23","author":"Lesser","year":"1967","journal-title":"J Appl Physiol"},{"key":"R11-20250601","doi-asserted-by":"crossref","first-page":"478","DOI":"10.4097\/kja.21345","article-title":"Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil","volume":"74","author":"Kim","year":"2021","journal-title":"Korean J Anesthesiol"},{"key":"R12-20250601","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cpt1975184377","article-title":"Commentary: a physiological approach to hepatic drug clearance","volume":"18","author":"Wilkinson","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"R13-20250601","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.bja.2018.01.018","article-title":"Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation","volume":"120","author":"Eleveld","year":"2018","journal-title":"Br J Anaesth"},{"key":"R14-20250601","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bja.2020.10.027","article-title":"Prospective clinical validation of the Eleveld propofol pharmacokinetic-pharmacodynamic model in general anaesthesia","volume":"126","author":"Vellinga","year":"2021","journal-title":"Br J Anaesth"},{"key":"R15-20250601","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/anae.14428","article-title":"Guidelines for the safe practice of total intravenous anaesthesia (TIVA): Joint Guidelines from the Association of Anaesthetists and the Society for Intravenous Anaesthesia","volume":"74","author":"Nimmo","year":"2019","journal-title":"Anaesthesia"},{"key":"R16-20250601","first-page":"1243","article-title":"Two cases of intraoperative awareness during intravenous anesthesia with propofol in morbidly obese patients","volume":"51","author":"Igarashi","year":"2002","journal-title":"Masui"},{"key":"R17-20250601","doi-asserted-by":"crossref","first-page":"862632","DOI":"10.3389\/fsurg.2022.862632","article-title":"Postoperative recovery outcomes for obese patients undergoing general anesthesia: a meta-analysis of randomized controlled trials","volume":"9","author":"Hu","year":"2022","journal-title":"Front Surg"},{"key":"R18-20250601","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/bja\/67.1.41","article-title":"Pharmacokinetic model driven infusion of propofol in children","volume":"67","author":"Marsh","year":"1991","journal-title":"Br J Anaesth"},{"key":"R19-20250601","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/00000542-199805000-00006","article-title":"The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers","volume":"88","author":"Schnider","year":"1998","journal-title":"Anesthesiology"},{"key":"R20-20250601","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1213\/ANE.0000000000000317","article-title":"Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis","volume":"119","author":"Cortinez","year":"2014","journal-title":"Anesth Analg"},{"key":"R21-20250601","first-page":"123","article-title":"Safe practice of total intravenous anesthesia with target-controlled infusion in taiwan: a recommendation","volume":"59","author":"Lai","year":"2021","journal-title":"Asian J Anesthesiol"},{"key":"R22-20250601","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/00000542-199809000-00004","article-title":"Remifentanil pharmacokinetics in obese versus lean patients","volume":"89","author":"Egan","year":"1998","journal-title":"Anesthesiology"},{"key":"R23-20250601","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/ALN.0000000000001634","article-title":"An allometric model of remifentanil pharmacokinetics and pharmacodynamics","volume":"126","author":"Eleveld","year":"2017","journal-title":"Anesthesiology"},{"key":"R24-20250601","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00000542-199701000-00004","article-title":"Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development","volume":"86","author":"Minto","year":"1997","journal-title":"Anesthesiology"},{"key":"R25-20250601","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bja.2020.05.051","article-title":"Target-controlled-infusion models for remifentanil dosing consistent with approved recommendations","volume":"125","author":"Eleveld","year":"2020","journal-title":"Br J Anaesth"},{"key":"R26-20250601","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/ALN.0b013e3181ae8460","article-title":"Is anesthesiology going soft?: trends in fragile pharmacology","volume":"111","author":"Egan","year":"2009","journal-title":"Anesthesiology"},{"key":"R27-20250601","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bja.2021.05.027","article-title":"Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment","volume":"127","author":"St\u00f6hr","year":"2021","journal-title":"Br J Anaesth"},{"key":"R28-20250601","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00540-022-03079-y","article-title":"A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice","volume":"36","author":"Masui","year":"2022","journal-title":"J Anesth"},{"key":"R29-20250601","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jcph.1552","article-title":"Time-to-event modeling for remimazolam for the indication of induction and maintenance of general anesthesia","volume":"60","author":"Lohmer","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"R30-20250601","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bja.2020.08.033","article-title":"Moving from dose to concentration: as easy as TCI!","volume":"125","author":"Egan","year":"2020","journal-title":"Br J Anaesth"},{"key":"R31-20250601","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/bja\/aex320","article-title":"Getting the dose right: anaesthetic drug delivery and the posological sweet spot","volume":"119","author":"Kuck","year":"2017","journal-title":"Br J Anaesth"}],"container-title":["Current Opinion in Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000001280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T22:00:12Z","timestamp":1748815212000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000001280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aco.0000000000001280","relation":{},"ISSN":["0952-7907","1473-6500"],"issn-type":[{"value":"0952-7907","type":"print"},{"value":"1473-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}